Showing 7451-7460 of 8238 results for "".
- Santalis Pharmaceuticals Starts Phase 2 Study of New Sandalwood Oil-based AD Therapyhttps://practicaldermatology.com/news/australias-santalis-pharmaceuticals-starts-phase-2-study-of-new-ad-therapy/2458445/Santalis Pharmaceuticals has enrolled the first patient in a Phase 2 Study of 5% East Indian Sandalwood Oil (EISO) cream for the treatment of atopic dermatitis (AD). Up to 60 patients aged 3 months to 65 with a clinically stable diagnosis of AD who have a total body surface
- FDA Bans 19 Ingredients from Hand Soapshttps://practicaldermatology.com/news/fda-no-more-antibacterials-allowed-in-consumer-soaps/2458446/Antibacterial soaps will soon be gone from store shelves, according to a new rule from the US Food and Drug Administration (FDA). This
- Vivacare and the National Rosacea Society Collaborate on Patient Education Resourcehttps://practicaldermatology.com/news/vivacare-and-the-national-rosacea-society-collaborate-on-patient-education-resource/2458448/Vivacare has launched a new Rosacea Education Kit to support dermatologists in the delivery of care to their rosacea patients. The Kit is available at no cost by enrolling online. Upon enrolling, dermatologists receive
- FDA Approves Enbrel Biosimilarhttps://practicaldermatology.com/news/fda-approves-enbrel-biosimilar/2458451/The U.S. Food and Drug Administration (FDA) approved Erelzi for multiple inflammatory diseases. Erelzi is a biosimilar to Enbrel (etanercept), which was originally licensed in 1998. The move is no surprise given the unanimous backing of an FDA advisory arm last month. There are now
- FDA Greenlights NDA for New Impetigo Treatmenthttps://practicaldermatology.com/news/fda-greenlights-nda-for-new-impetigo-treatment/2458449/The U.S. Food and Drug Administration (FDA) has accepted Medimetriks Pharmaceuticals, Inc.'s New Drug Application (NDA) for their novel impetigo treatment, ozenoxacin cream, 1%. Ozenoxacin cream is a non-fluorinated quinolone. The
- Cetaphil® Marks Fifth Year of Support for CSDF and Camp Wonderhttps://practicaldermatology.com/news/cetaphil-marks-fifth-year-of-support-for-csdf-and-camp-wonder/2458452/Galderma Laboratories, L.P., makers of Cetaphil, is celebrating the fifth consecutive year of its "Meaningphil™" partnership with the Children's Skin Disease Foundation (CSDF) and Camp Wonder.</
- Chris Payne Named Chief Marketing Officer at PCA Skinhttps://practicaldermatology.com/news/chris-payne-named-chief-marketing-officer-at-pca-skin/2458454/Chris Payne has been named Chief Marketing Officer at Scottsdale, AZ-based PCA Skin. In this role, Payne will be responsible for leading all marketing and communication initiatives to drive growth of PCA SKIN through both professional and consum
- Kybella for Men May Mean Buh-Bye Beardshttps://practicaldermatology.com/news/kybella-for-men-may-mean-buh-bye-beards/2458456/If Allergan’s double-chin melting injectable Kybella were to really take off among men, we may be seeing a lot fewer beards, jokes bearded Washington DC –based dermatologist Terrence Keaney, MD. Male aesthetics is a growing market,
- Freedom Laser Therapy Launches iRESTORE Hair Growth Systemhttps://practicaldermatology.com/news/freedom-laser-therapy-launches-irestore-hair-growth-system/2458457/Freedom Laser Therapy is rolling out the iRestore Hair Growth System. The hands-free iRestore Hair Growth System is US Food and Drug Administr
- Most Indoor Tanners Not in Favor of #Banthetan Movementhttps://practicaldermatology.com/news/most-indoor-tanners-not-in-favor-of-banthetan-movement/2458464/Most young adult women who regularly visit indoor tanning salons do support the introduction of policies to make it safer, but are against a total ban. The new findings appear in Translational Behavior